Patents by Inventor Namrata Patil

Namrata Patil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Afucosylated Anti-FGFR2IIIB Antibodies
    Publication number: 20220168416
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 2, 2022
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Afucosylated anti-FGFR2IIIB antibodies
    Patent number: 11235059
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • METHOD OF MONITORING EFFECTIVENESS OF IMMUNOTHERAPY OF CANCER PATIENTS
    Publication number: 20210292851
    Abstract: The invention is a method of determining a likelihood that a cancer patient will respond to immunotherapy based on a mutation metric obtained by sequencing a small panel of nucleic acid targets in patient's cell-free DNA.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 23, 2021
    Inventors: Aarthi Balasubramanyam, Yuqiu Jiang, John Palma, Namrata Patil, Johnny Wu, Stephanie Yaung, Wei Zou
  • Afucosylated Anti-FGFR2IIIB Antibodies
    Publication number: 20190175730
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 13, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies
    Patent number: 10172937
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 8, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES
    Publication number: 20160339100
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: May 27, 2016
    Publication date: November 24, 2016
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES
    Publication number: 20150050273
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 19, 2015
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton